Literature DB >> 22252429

Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer.

Terry Hyslop1, David S Weinberg, Stephanie Schulz, Alan Barkun, Scott A Waldman.   

Abstract

BACKGROUND AND OBJECTIVES: Recurrence in lymph node-negative (pN0) colorectal cancer suggests the presence of undetected occult metastases. Occult tumor burden in nodes estimated by GUCY2C RT-qPCR predicts risk of disease recurrence. This study explored the impact of the number of nodes analyzed by RT-qPCR (analytic) on the prognostic utility of occult tumor burden.
METHODS: Lymph nodes (range: 2-159) from 282 prospectively enrolled pN0 colorectal cancer patients, followed for a median of 24 months (range: 2-63), were analyzed by GUCY2C RT-qPCR. Prognostic risk categorization defined using occult tumor burden was the primary outcome measure. Association of prognostic variables and risk category were defined by multivariable polytomous and semi-parametric polytomous logistic regression.
RESULTS: Occult tumor burden stratified this pN0 cohort into categories of low (60%; recurrence rate (RR) = 2.3% [95% CI 0.1-4.5%]), intermediate (31%; RR = 33.3% [23.7-44.1%]), and high (9%; RR = 68.0% [46.5-85.1%], P < 0.001) risk of recurrence. Beyond race and T stage, the number of analytic nodes was an independent marker of risk category (P < 0.001). When >12 nodes were analyzed, occult tumor burden almost completely resolved prognostic risk classification of pN0 patients.
CONCLUSIONS: The prognostic utility of occult tumor burden assessed by GUCY2C RT-qPCR is dependent on the number of analytic lymph nodes.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22252429      PMCID: PMC3370134          DOI: 10.1002/jso.23051

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  35 in total

Review 1.  Systemic therapy for colorectal cancer.

Authors:  Jeffrey A Meyerhardt; Robert J Mayer
Journal:  N Engl J Med       Date:  2005-02-03       Impact factor: 91.245

2.  Limitations with light microscopy in the detection of colorectal cancer cells.

Authors:  C L Hitchcock; J Sampsel; D C Young; E W Martin; M W Arnold
Journal:  Dis Colon Rectum       Date:  1999-08       Impact factor: 4.585

3.  Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.

Authors:  Terry Hyslop; David S Weinberg; Stephanie Schulz; Alan Barkun; Scott A Waldman
Journal:  Cancer       Date:  2011-09-01       Impact factor: 6.860

4.  Two-sided confidence intervals for the single proportion: comparison of seven methods.

Authors:  R G Newcombe
Journal:  Stat Med       Date:  1998-04-30       Impact factor: 2.373

5.  Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer.

Authors:  B Cagir; A Gelmann; J Park; T Fava; A Tankelevitch; E W Bittner; E J Weaver; J P Palazzo; D Weinberg; R D Fry; S A Waldman
Journal:  Ann Intern Med       Date:  1999-12-07       Impact factor: 25.391

6.  Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance.

Authors:  C Ratto; L Sofo; M Ippoliti; M Merico; M Bossola; F M Vecchio; G B Doglietto; F Crucitti
Journal:  Dis Colon Rectum       Date:  1999-02       Impact factor: 4.585

7.  Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues.

Authors:  S L Carrithers; M T Barber; S Biswas; S J Parkinson; P K Park; S D Goldstein; S A Waldman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

Review 8.  The staging of colorectal cancer: 2004 and beyond.

Authors:  Carolyn C Compton; Frederick L Greene
Journal:  CA Cancer J Clin       Date:  2004 Nov-Dec       Impact factor: 508.702

9.  Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.

Authors:  T E Le Voyer; E R Sigurdson; A L Hanlon; R J Mayer; J S Macdonald; P J Catalano; D G Haller
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544

10.  Micrometastases and survival in stage II colorectal cancer.

Authors:  G J Liefers; A M Cleton-Jansen; C J van de Velde; J Hermans; J H van Krieken; C J Cornelisse; R A Tollenaar
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

View more
  5 in total

Review 1.  Guanylyl cyclase C as a biomarker in colorectal cancer.

Authors:  Terry Hyslop; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

2.  Lymph node pooling: a feasible and efficient method of lymph node molecular staging in colorectal carcinoma.

Authors:  Natalia Rakislova; Carla Montironi; Iban Aldecoa; Eva Fernandez; Josep Antoni Bombi; Mireya Jimeno; Francesc Balaguer; Maria Pellise; Antoni Castells; Miriam Cuatrecasas
Journal:  J Transl Med       Date:  2017-01-14       Impact factor: 5.531

3.  Combined detection of the expression of Nm23-H1 and p53 is correlated with survival rates of patients with stage II and III colorectal cancer.

Authors:  Yinying Wu; Yi Li; Xiaoai Zhao; Danfeng Dong; Chunhui Tang; Enxiao Li; Qianqian Geng
Journal:  Oncol Lett       Date:  2016-11-23       Impact factor: 2.967

4.  Molecular staging of node negative patients with colorectal cancer.

Authors:  Terry Hyslop; Scott A Waldman
Journal:  J Cancer       Date:  2013-03-01       Impact factor: 4.207

5.  Molecularly determined total tumour load in lymph nodes of stage I-II colon cancer patients correlates with high-risk factors. A multicentre prospective study.

Authors:  Iban Aldecoa; Begoña Atares; Jordi Tarragona; Laia Bernet; Jose Domingo Sardon; Teresa Pereda; Carlos Villar; M Carmen Mendez; Elvira Gonzalez-Obeso; Kepa Elorriaga; Guadalupe Lopez Alonso; Javier Zamora; Nuria Planell; Jose Palacios; Antoni Castells; Xavier Matias-Guiu; Miriam Cuatrecasas
Journal:  Virchows Arch       Date:  2016-07-22       Impact factor: 4.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.